OptimizeRx (OPRX) to Release Quarterly Earnings on Thursday

OptimizeRx (NASDAQ:OPRX) will likely be announcing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect OptimizeRx to post earnings of $0.03 per share and revenue of $23.8330 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $18.78 on Wednesday. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $22.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The company has a 50 day moving average price of $18.88 and a 200-day moving average price of $15.00. The firm has a market cap of $348.65 million, a price-to-earnings ratio of -34.78 and a beta of 1.25.

Wall Street Analyst Weigh In

OPRX has been the subject of a number of recent analyst reports. JMP Securities lifted their price objective on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, October 10th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. UBS Group set a $23.00 price objective on OptimizeRx in a research report on Friday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of OptimizeRx in a research report on Wednesday, October 8th. Finally, Roth Capital reissued a “buy” rating on shares of OptimizeRx in a report on Friday, August 8th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.39.

Insider Buying and Selling at OptimizeRx

In related news, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer owned 188,916 shares of the company’s stock, valued at approximately $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Patrick D. Spangler sold 11,120 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the completion of the sale, the director directly owned 44,215 shares of the company’s stock, valued at $773,320.35. This represents a 20.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.60% of the stock is owned by corporate insiders.

Institutional Trading of OptimizeRx

Hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the 2nd quarter valued at approximately $44,000. BNP Paribas Financial Markets grew its position in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the period. WINTON GROUP Ltd purchased a new position in OptimizeRx in the second quarter worth approximately $286,000. Massar Capital Management LP purchased a new position in OptimizeRx in the second quarter worth approximately $297,000. Finally, American Century Companies Inc. grew its holdings in shares of OptimizeRx by 52.5% during the 2nd quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock worth $325,000 after purchasing an additional 8,286 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.